FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...
Revolution Medicines (RVMD) stock surged 38% after Phase 3 data showed daraxonrasib achieved 13.2 months survival vs. 6.7 months with chemotherapy.
Stories by SWNS on MSN
K9 Rex helps locate missing 7-year-old girl in Colorado in under 12 minutes
A police search dog helped locate a 7-year-old girl after she went missing for nearly two hours in Aurora, Colorado, on April ...
Kura Oncology, Inc. remains a Buy, driven by ziftomenib's launch and promising combination trial data in AML. Learn more ...
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...
Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data ...
AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.
By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...
Revolution Medicines has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...
This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn.Boehringer Ingelheim today announced that The New ...
The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results